Home » Stocks » VKTX

Viking Therapeutics, Inc. (VKTX)

Stock Price: $6.74 USD -0.14 (-2.03%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $7.18 +0.44 (6.53%) Feb 26, 7:58 PM
Market Cap 499.66M
Revenue (ttm) n/a
Net Income (ttm) -39.50M
Shares Out 72.60M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $6.74
Previous Close $6.88
Change ($) -0.14
Change (%) -2.03%
Day's Open 6.97
Day's Range 6.62 - 7.05
Day's Volume 1,153,719
52-Week Range 3.26 - 10.09

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 month ago

SAN DIEGO, Jan. 6, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabo...

PRNewsWire - 1 month ago

SAN DIEGO, Jan. 5, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabo...

Seeking Alpha - 2 months ago

The entire NASH space was shaken by Genfit's trial fiasco; Viking has its own problems. The drug may actually be a wonderful new therapy for NASH/NAFLD patients; however, whether VKTX will ben...

The Motley Fool - 3 months ago

Aprea Therapeutics, Viking Therapeutics, and Vaxart could all generate life-changing returns for early shareholders.

Other stocks mentioned: APRE, VXRT
PRNewsWire - 3 months ago

SAN DIEGO, Nov. 10, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metab...

Seeking Alpha - 3 months ago

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 5 months ago

SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Viking Therapeutics, Inc.

PRNewsWire - 5 months ago

SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- Viking Therapeutics, Inc.

The Motley Fool - 5 months ago

Bargain stocks don't come much cheaper than this.

Other stocks mentioned: OPK
PRNewsWire - 5 months ago

SAN DIEGO, Aug. 28, 2020 /PRNewswire/ -- Viking Therapeutics, Inc.

PRNewsWire - 6 months ago

SAN DIEGO, Aug. 20, 2020 /PRNewswire/ -- Viking Therapeutics, Inc.

Seeking Alpha - 6 months ago

Viking Therapeutics: Another Year In Review

24/7 Wall Street - 6 months ago

The second half of 2020 is well underway, and with markets recovering, one of the strongest industries leading the charge has been biotech.

Other stocks mentioned: DVAX, IBB, IMGN, LXRX, XNCR
Seeking Alpha - 6 months ago

Viking Therapeutics, Inc.'s (VKTX) CEO Brian Lian on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 6 months ago

SAN DIEGO, July 29, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabol...

PRNewsWire - 7 months ago

SAN DIEGO, July 22, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metab...

GuruFocus - 8 months ago

The risk of investing in Viking Therapeutics Inc. (NASDAQ:VKTX) may not be worth the potential rewards, according to a December article in Equities News.

Benzinga - 8 months ago

Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher on Friday. BMO Capital initiated coverage on the stock with an Outperform rating and a price target of $14 per share.

Kiplinger - 9 months ago

Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.

Other stocks mentioned: ATRA, DVAX, FIXX, GTHX, IMGN, KDMN
Benzinga - 9 months ago

Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher on Tuesday, after Chardan initiated coverage on the company's stock with a Buy rating and $15 price target.

Seeking Alpha - 9 months ago

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q1 2020 Results - Earnings Call Transcript

The Motley Fool - 10 months ago

The small-cap pharma stock didn't stand a chance in the broader market volatility.

The Motley Fool - 11 months ago

Healthcare bargain hunters can find good values in quality low-priced stocks.

Other stocks mentioned: AMGN, AMRX, MRTX, VSTM
The Motley Fool - 11 months ago

These clinical-stage drugmakers could be a steal at current levels.

Other stocks mentioned: ADAP, AGEN, GILD
Seeking Alpha - 11 months ago

Flipping The Script On Viking Therapeutics

Seeking Alpha - 11 months ago

Viking Therapeutics: Time To Start Scaling In

Seeking Alpha - 1 year ago

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q4 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

Targeting a large and growing disease state, this drug developer's stock requires patience to reap future rewards.

24/7 Wall Street - 1 year ago

One reason that investors continue to do business with full-service brokerage firms is they generate researched and studied investment ideas.

Other stocks mentioned: BTAI, RARE
The Motley Fool - 1 year ago

HOOKIPA Pharma and Viking Therapeutics could catch first at some point this year. Here's why.

Other stocks mentioned: HOOK
Benzinga - 1 year ago

The S&P 500 closed out 2019 with another strong month in December. However, analysts remain optimistic on some top stocks heading into 2020.

Other stocks mentioned: AMZN, CPRX, GLUU, VSLR
Benzinga - 1 year ago

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

Other stocks mentioned: AKCA, AMAG, AXSM, CRON, EIDX, HRTX, LGND, PRTK, PTE, XON, ZIOP
Seeking Alpha - 1 year ago

I'm Picking Viking Therapeutics For NASH

The Motley Fool - 1 year ago

Can the stock march even higher after its recent rally?

The Motley Fool - 1 year ago

The biotech's Q3 update fired up investors.

Seeking Alpha - 1 year ago

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q3 2019 Results - Earnings Call Transcript

24/7 Wall Street - 1 year ago

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CPE, GLMD, SIEN, TELL
The Motley Fool - 1 year ago

The biotech rivals each aim to dominate the treatment market for non-alcoholic steatohepatitis (NASH).

Other stocks mentioned: ICPT
Seeking Alpha - 1 year ago

VKTX produced strong data in reducing liver fat in NAFLD patients.

24/7 Wall Street - 1 year ago

This has been a hard year for biotech. It seems that both Democrats and Republicans are wanting to target drug prices, and fears of universal health care in the years ahead would mean lower pr...

Other stocks mentioned: AKCA, AMAG, EIDX, LGND, MNKD, MRNA, PRTK
The Motley Fool - 1 year ago

What you need to know about this high-risk, high-reward biotech stock.

The Motley Fool - 1 year ago

It's one of the more promising companies in the race to develop a successful NASH treatment. Will patient investors be rewarded?

Seeking Alpha - 1 year ago

Viking Therapeutics' (VKTX) CEO Brian Lian on Q2 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

The catalysts these companies enjoy could translate into big returns for shareholders in the coming decades.

Other stocks mentioned: PM, WELL
The Motley Fool - 1 year ago

They're risky. You'll have to wait years before any significant revenue comes in.

Other stocks mentioned: CARA, EDIT
Seeking Alpha - 1 year ago

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q1 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

Viking's shares received a boost from a pair of catalysts last month.

The Motley Fool - 1 year ago

Are intrepid short-sellers taking advantage of misguided enthusiasm?

Other stocks mentioned: TXMD
The Motley Fool - 1 year ago

Bargain hunting? These out-of-favor biotech and e-commerce stocks should appeal to value investors.

Other stocks mentioned: XPO
The Motley Fool - 1 year ago

Investors were impressed with updated results for the company's lead candidate.

About VKTX

Viking Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II c... [Read more...]

Industry
Biotechnology
IPO Date
Apr 29, 2015
CEO
Brian Lian
Employees
18
Stock Exchange
NASDAQ
Ticker Symbol
VKTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 14 analysts, the average rating for VKTX stock is "Strong Buy." The 12-month stock price forecast is 19.71, which is an increase of 192.43% from the latest price.

Price Target
$19.71
(192.43% upside)
Analyst Consensus: Strong Buy